Continuous vs. batch production
While widely adopted in other industries, continuous manufacturing is only just starting to be explored as a production process by…
Contract manufacturing trends: part two
Contract manufacturing organisations (CMOs) are operating in an increasingly demanding space. Low volume, complex targeted therapies are dominating drug development pipelines, meaning API manufacturers must be flexible enough to offer a wide range of chemistries and scales of manufacture to accommodate their customers’ requirements.
In the second part of a contract manufacturing roundtable in Manufacturing Chemist our CEO, Kevin Cook, discusses how contract partners need to adapt to the new landscape and take advantage of opportunities for growth and development. Read the full article here: http://bit.ly/2rUmZjm.
Related
CEO spotlight: Kevin Cook
A conversation with Kevin Cook about CDMO-sponsor partnerships and outsourcing Kevin Cook, CEO at Sterling Pharma Solutions recently spoke with…
Hazardous chemistry in drug development
The growing demand for hazardous chemistry brings new risks that require both chemistry and engineering expertise As new chemical entities…
Controlled and effective hazardous chemistry
There is a growing demand for hazardous chemistry techniques for synthetic manufacturing processes, propelled by the increasing complexity of new…